Comparative Pharmacology
Head-to-head clinical analysis: SOLIFENACIN SUCCINATE versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOLIFENACIN SUCCINATE versus VESICARE.
SOLIFENACIN SUCCINATE vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Solifenacin is a competitive muscarinic receptor antagonist. It binds selectively to M3 muscarinic receptors, inhibiting acetylcholine action on smooth muscle of the urinary bladder, reducing detrusor overactivity and increasing bladder capacity.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
5 mg orally once daily, may increase to 10 mg once daily if tolerated.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 45-68 hours (mean ~55 hours) in healthy adults, allowing once-daily dosing.
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Primarily renal: ~69% as metabolites (including active metabolite 4R-hydroxy solifenacin) and ~7% as unchanged drug. Fecal excretion accounts for ~23% (mainly as metabolites).
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category A/B
Category C
Anticholinergic
Anticholinergic